Hormone receptor-positive (ER+/PR+; ER+/PR-; ER-/PR+, including HER2-equivocal) accounted for 59.7% and hormone receptor-negative (ER-/PR- including HER2-equivocal), 20.6% of the cases; approximately 16% were triple-negative breast cancer (TNBC) and 4.6% were HER2-enriched. Here, ERBB2 is linked to triple-negative breast carcinoma.